Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.

ABSTRACT:

Background

Reducing nivolumab dose intensity could increase patients' life quality and decrease the financial burden while maintaining efficacy. The aims of this study were to develop a population PK model of nivolumab based on data from unselected metastatic cancer patients and to simulate extended-interval regimens allowing to maintain minimal effective plasma concentrations (MEPC).

Methods

Concentration-time data (992 plasma nivolumab concentrations, 364 patients) were modeled using a two-compartment model with linear elimination clearance in Monolix software. Extended-interval regimens allowing to maintain steady-state trough concentrations (C_min,ss) above the MEPC of 2.5 mg/L or 1.5 mg/L in >90% of patients were simulated.

Results

Increasing 3-times th

SUBMITTER: Puszkiel A 

PROVIDER: S-EPMC11130267 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature